Free public records show AMAG Pharmaceuticals, Inc. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by AMAG Pharmaceuticals, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
2 active studies led by AMAG Pharmaceuticals, Inc., of 24 in all
Source: ClinicalTrials.gov, Studies with AMAG Pharmaceuticals, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 792977.
Studies AMAG Pharmaceuticals, Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with AMAG Pharmaceuticals, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show AMAG Pharmaceuticals, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets AMAG Pharmaceuticals, Inc. is in.
Stories on the topics AMAG Pharmaceuticals, Inc. works in.
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
170 of 194 WHO member states report use of traditional medicine. Herbal products are popular, but quality and…
ReadSearch all reports for AMAG Pharmaceuticals, Inc. All companies